Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GIVINOSTAT versus hydroxyurea in high‑risk JAK2V617F‑positive polycythemia vera (GIV-IN PV TRIAL)
2022-502276-23-00Phase 3Authorised
- Sponsor
- Italfarmaco
- Start
- Apr 2024
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 16
01
Overview
Phase 3, randomised, open-label trial of givinostat in polycythemia vera (PV) (2 arms), sponsored by Italfarmaco. Primary endpoints: Composite response at Week 48 (core treatment phase) and Treatment-emergent adverse events in extended treatment phase. Planned start Apr 2024; status: authorised.
02
Drugs
givinostat
03
Conditions
polycythemia vera (PV)
Beyond the preview
Go deeper on 2022-502276-23-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502276-23-00.